公开(公告)号：US20180236043A1

公开(公告)日：2018-08-23

申请号：US15882228

申请日：2018-01-29

Applicant: Temple University of the Commonwealth System of Higher Education

Inventor： Kamel KHALILI ,  Wenhui HU

IPC: A61K38/46 ,  C12N7/00 ,  A61K9/00 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  C12N9/22 ,  C12N15/11

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus. A method of treating a subject having or at risk for having a virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus, and causing neither genotoxicity nor off-target editing to the host.

公开(公告)号：US20180236041A1

公开(公告)日：2018-08-23

申请号：US15882197

申请日：2018-01-29

Applicant: Temple University of the Commonwealth System of Higher Education

Inventor： Kamel KHALILI ,  Wenhui HU

IPC: A61K38/46 ,  C12N7/00 ,  A61K9/00 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  C12N9/22 ,  C12N15/11

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A method of treating a subject having or at risk for having a virus infection, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the virus, and completely excising a fragment of greater than 9000-bp of integrated proviral DNA that spanned from its 5′- to 3′-LTRs. A method of treating a subject having or at risk for having a genetic caused disease, by administering a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs that are complementary to two target sequences spanning from the sequence of the subjects DNA greater than 9000-bp that is chromosomally integrated and causes the genetic caused disease, and excising the chromosomally integrated sequence.

公开(公告)号：US20180228875A1

公开(公告)日：2018-08-16

申请号：US15950227

申请日：2018-04-11

Applicant: Temple University of the Commonwealth System of Higher Education

Inventor： Kamel Khalili ,  Wenhui HU

IPC: A61K38/46 ,  A61K9/00 ,  C12N9/22 ,  C12N7/00 ,  C12N15/11 ,  A61K45/06 ,  A61K48/00 ,  A61K35/12

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A personalized method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus, by determining a nucleic acid sequence of the HIV-1 proviral DNA harbored by a subject, designing two or more different multiplex guide RNAs (gRNAs) complementary to the HIV-1 proviral DNA sequences in the subject, administering to the subject a therapeutically effective amount of a composition comprising a CRISPR-associated endonuclease, and the two or more different multiplex gRNAs, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, and eradicating the HIV-1 proviral DNA from the host cell.

公开(公告)号：US20180214521A1

公开(公告)日：2018-08-02

申请号：US15939710

申请日：2018-03-29

Applicant: Temple University of the Commonwealth System of Higher Education

Inventor： Kamel Khalili ,  Wenhui Hu

IPC: A61K38/46 ,  C12N15/11 ,  A61K35/12 ,  A61K48/00 ,  C12N7/00 ,  C12N9/22 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A method of immunizing a subject at risk of HIV-1 virus infection, by administering to the subject a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and preventing HIV-1 virus infection in the subject.

公开(公告)号：US20180169194A1

公开(公告)日：2018-06-21

申请号：US15884427

申请日：2018-01-31

Applicant: Temple University of the Commonwealth system of Higher Education

Inventor： Kamel KHALILI ,  Wenhui Hu

IPC: A61K38/46 ,  C12N15/11 ,  A61K35/12 ,  A61K48/00 ,  C12N7/00 ,  C12N9/22 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K38/465 ,  A61K9/0034 ,  A61K35/12 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N7/00 ,  C12N9/22 ,  C12N15/111 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2740/16063 ,  C12Y301/21

Abstract: A method of treating a subject having a retroviral infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5′- to 3′-LTRs of the sequence in the retrovirus, and eradicating the retroviral infection. A method of immunizing a subject at risk of retroviral infection, by administering a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of a retrovirus to the subject, and preventing retroviral infection in the subject.

公开(公告)号：US20170362265A1

公开(公告)日：2017-12-21

申请号：US15453836

申请日：2017-03-08

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Sachin S. SHIVATARE

IPC: C07H5/06 ,  A61K31/702 ,  C12N9/10 ,  C07K16/10 ,  C12P19/28

CPC classification number: C07H5/06 ,  A61K31/702 ,  C07K16/1045 ,  C08B37/006 ,  C12N9/107 ,  C12N2740/16063 ,  C12P19/04 ,  C12P19/28 ,  G01N33/50 ,  G01N33/532 ,  G01N33/56988 ,  G01N33/68 ,  G01N33/6893

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

公开(公告)号：US20170333457A1

公开(公告)日：2017-11-23

申请号：US15671360

申请日：2017-08-08

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Brian AGNEW ,  Upinder SINGH ,  Scott GRECIAN

IPC: A61K31/655 ,  A61K31/7008 ,  C12N7/00

CPC classification number: A61K31/655 ,  A61K31/7008 ,  C12N7/00 ,  C12N2710/14151 ,  C12N2710/14163 ,  C12N2740/16051 ,  C12N2740/16063

Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.

公开(公告)号：US20160002319A1

公开(公告)日：2016-01-07

申请号：US14771337

申请日：2014-02-28

Applicant: THERABIOLI, INC.

Inventor： M. Scott Killian ,  Evelin Szakal ,  Girish N. Vyas

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/21 ,  C12N7/00 ,  C07K16/00 ,  C07K14/005

CPC classification number: C07K16/1063 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  C07K14/005 ,  C07K16/005 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/16051 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  G01N33/56983 ,  G01N33/56988

Abstract: The present invention relates to a method for reducing the occurance and/or severity of viral infections. The method embodies procedures for expanding HIV from the blood of HIV antibody negative donors and deriving a non-infectious virus particle product that is antigenic. The procedures for deriving the antigenic, non-infectious virus particle product are optimally designed to maintain the integrity of the envelope proteins while maximizing the depletion of capsid proteins and RNA. The resulting virus particle product, when introduced into humans or non-human animals, enables the production of antibodies that target the natural envelope macromolecular structure that is required for infectivity. The present invention can be applied to producing virus stocks from the blood of HIV-seronegative donors, for deriving non-infectious virus particles that retain intact envelope proteins, for producing anti-viral antibodies, and for administering anti-virus antibodies to patients.

Abstract translation: 本发明涉及一种减少病毒感染发生和/或严重程度的方法。 该方法体现了从HIV抗体阴性供体的血液中扩展HIV的方法，并得到抗原性的非感染性病毒颗粒产物。 用于衍生抗原非感染性病毒颗粒产物的程序被最佳设计以保持包膜蛋白的完整性，同时最大化衣壳蛋白和RNA的消耗。 所得到的病毒颗粒产物在引入人类或非人类动物中时，能够产生靶向传染性所需的天然包膜大分子结构的抗体。 本发明可以应用于从HIV-血清阴性供体供体的血液中产生病毒颗粒，用于产生保留完整包膜蛋白的非感染性病毒颗粒，产生抗病毒抗体，以及向患者施用抗病毒抗体。

公开(公告)号：US09120849B2

公开(公告)日：2015-09-01

申请号：US11929089

申请日：2007-10-30

Applicant: Gregory R. Chiklis ,  James C. D. Hengst

Inventor： Gregory R. Chiklis ,  James C. D. Hengst

IPC: C12Q1/68 ,  C12N7/04 ,  C07K14/005 ,  C12N7/00

CPC classification number: C12Q1/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10163 ,  C12N2740/15022 ,  C12N2740/16022 ,  C12N2740/16063 ,  C12N2740/16222 ,  C12N2770/24322 ,  C12N2770/24363 ,  C12Q1/6888 ,  C12Q1/689 ,  C12Q2600/166 ,  Y02A50/54 ,  Y02A50/59

Abstract: The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making and using the control material.

公开(公告)号：US08932818B2

公开(公告)日：2015-01-13

申请号：US13058613

申请日：2009-08-13

Applicant: Sergey V. Paushkin ,  Nikolai A. Naryshkin ,  Ellen Welch

Inventor： Sergey V. Paushkin ,  Nikolai A. Naryshkin ,  Ellen Welch

IPC: C12Q1/68 ,  C12Q1/66 ,  C12Q1/48 ,  C12Q1/34 ,  C12Q1/02

CPC classification number: A61K31/4035 ,  C12N7/00 ,  C12N15/11 ,  C12N2710/16663 ,  C12N2720/00063 ,  C12N2740/11063 ,  C12N2740/12063 ,  C12N2740/14063 ,  C12N2740/15063 ,  C12N2740/16063 ,  C12N2770/00063 ,  C12N2770/10063 ,  C12N2770/12063 ,  C12N2770/20063 ,  C12N2770/38063 ,  C12N2795/10263 ,  C12N2795/10363 ,  C12Q1/66 ,  C12Q1/6897 ,  Y02A50/491

Abstract: The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation of compounds that modulate ribosomal frameshifting. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal frameshifting and the use of compounds that modulate the efficiency of programmed ribosomal frameshifting to inhibit the replication or infectivity of viruses that employ programmed ribosomal frameshifting.

Abstract translation: 本发明涉及调节核糖体移码和核酸构建体的化合物，其用于鉴定或验证调节核糖体移码的化合物的方法。 特别地，本发明涉及核酸构建体用于鉴定或验证能够调节编程的核糖体移码效率的化合物的用途，以及调节编程的核糖体移码效率以抑制病毒的复制或感染性的化合物的用途， 采用编程的核糖体移码。